Cart
sales@molnova.com
MLN1117
CAS No. 1268454-23-4
MLN1117 ( INK1117;TAK-117;TAK117;Serabelisib;INK 1117 )
Catalog No. M11125 CAS No. 1268454-23-4
MLN1117 (INK1117,TAK-117, Serabelisib) is a potent, selective PI3K p110α inhibitor with IC50 of 15 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 48 | In Stock |
|
| 5MG | 76 | In Stock |
|
| 10MG | 105 | In Stock |
|
| 25MG | 213 | In Stock |
|
| 50MG | 312 | In Stock |
|
| 100MG | 492 | In Stock |
|
| 500MG | 1053 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMLN1117
-
NoteResearch use only, not for human use.
-
Brief DescriptionMLN1117 (INK1117,TAK-117, Serabelisib) is a potent, selective PI3K p110α inhibitor with IC50 of 15 nM.
-
DescriptionMLN1117 (INK1117,TAK-117, Serabelisib) is a potent, selective PI3K p110α inhibitor with IC50 of 15 nM, displays >300-fold selectivity over p110β/γ/δ and mTOR; inhibits AKT phosphorylation and growth in PIK3CA mutant breast cancer cells with IC50 of 2 uM, significantly suppresses B cell proliferation driven by anti-IgM alone but not by anti-IgM plus IL-4; abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma combined with alisertib.Breast Cancer Phase 2 Clinical
-
SynonymsINK1117;TAK-117;TAK117;Serabelisib;INK 1117
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptormTOR;p110α;p110β;p110γ;p110δ
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number1268454-23-4
-
Formula Weight363.37
-
Molecular FormulaC19H17N5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 6.4 mg/mL (Need ultrasonic or warming)
-
SMILESO=C(C1=CN=C2C=CC(C3=CC=C(OC(N)=N4)C4=C3)=CN21)N5CCOCC5
-
Chemical NameMethanone, [6-(2-amino-5-benzoxazolyl)imidazo[1,2-a]pyridin-3-yl]-4-morpholinyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. So L, et al. J Biol Chem. 2013 Feb 22;288(8):5718-31.
2. Juric D, et al. Clin Cancer Res. 2017 Sep 1;23(17):5015-5023.
3. Islam S, et al. Oncotarget. 2017 Nov 1;8(59):100326-100338.
4. Yea SS, et al. PLoS One. 2014 Jun 10;9(6):e99486.
2. Juric D, et al. Clin Cancer Res. 2017 Sep 1;23(17):5015-5023.
3. Islam S, et al. Oncotarget. 2017 Nov 1;8(59):100326-100338.
4. Yea SS, et al. PLoS One. 2014 Jun 10;9(6):e99486.
molnova catalog
related products
-
Vps34 inhibitor PIK-...
Vps34 inhibitor PIK-III (PIK-III) is a potent, selective inhibitor of Vps34 with IC50 of 18 nM.
-
NVP-BKM120
NVP-BKM120 (BKM-120, Buparlisib)is a potent, selective, orally bioavailable inhibitor of class I PI3K isoforms.
-
NIBR-17
NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
